Circular Genomics’ move to the Lilly Gateway Labs community will enhance scientific collaboration and innovation to foster the development of its Alzheimer’s disease diagnostic and prognostic blood ...
Company taps John R. Quain, Norbert Gleicher, MD, Carol Hanna, Ph.D, Jon Hennebold, Ph.D, and Stephen Turner, Ph.D to its world-class team to advance responsible genomic medicine. NEW YORK--(BUSINESS ...
New clinical data highlights circular RNAs (circRNAs) as a novel, non-invasive blood biomarker platform for the early detection of Alzheimer's Disease (AD). The research demonstrates that circRNAs ...
The first-ever sequencing of the human genome cost $2.7 billion. Today, the service 23andMe offers personal genome sequencing for less than $200. And for students enrolled in Cornell’s personal ...
Financing accelerates clinical validation and commercial readiness, as circular RNAs emerge as a new category of brain-derived blood biomarkers with best-in-class performance SAN DIEGO, Dec. 1, 2025 ...
Inherited diseases should not dictate human fate. Today, with advances in genomics, a different future is within reach. In this new era of genomic medicine, Manhattan Genomics, led by serial biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results